Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Immunoradiotherapy Combinations in Metastatic Solid Tumors
2023-508529-29-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tecaginlimab and pembrolizumab in Nonhematologic neoplasms, sponsored by Genmab. Primary endpoints: Dose Limiting Toxicities (DLTs) in Part 1 and Number of Participants with Abscopal Response in Non-irradiated Target Lesions in Part 2. Started Aug 2024; status: completed.
02
Drugs
tecaginlimabpembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-508529-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508529-29-00.